Spero Therapeutics, Inc.
SPRO Nasdaq
SEC CIK 1701108
Follow Spero Therapeutics
Weekly email: filings, results
Revenue, last quarter
$0
Net income
−$44.3M
−499.8% vs same quarter last year
EPS, diluted
−$0.76
−484.6% vs same quarter last year
Operating cash flow
−$42.6M
−344.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $12.6M | $8.6M |
| FY24 | $371K | −$68.6M |
| FY23 | $933K | $22.8M |
| FY22 | $2.5M | −$46.4M |
| FY21 | $3.1M | −$89.8M |
| FY20 | $258K | −$78.3M |
| FY19 | $4.7M | −$60.9M |
| FY18 | $4M | −$41.7M |
| FY17 | $2M | −$38.7M |
| FY16 | $335K | −$25.5M |
| FY15 | - | −$10.2M |
| FY14 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | 50.2% | 68.1% |
| FY24 | −19773.9% | −18481.4% |
| FY23 | 2302.4% | 2444.4% |
| FY22 | −1685.9% | −1854.4% |
| FY21 | −2865.5% | −2925.1% |
| FY20 | −30664% | −30348.8% |
| FY19 | −1333.1% | −1284.3% |
| FY18 | −1079.3% | −1051.4% |
| FY17 | −2108.6% | −1957.7% |
| FY16 | −9916.7% | −7609.3% |
| FY15 | - | - |
| FY14 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | - |
| FY21 | - |
| FY20 | −$86M |
| FY19 | −$50.3M |
| FY18 | −$42.1M |
| FY17 | −$39.1M |
| FY16 | −$29.8M |
| FY15 | −$9.8M |
| FY14 | - |
- Spero Therapeutics
- Healthcare median
Show the numbers
| Year | Spero Therapeutics | Healthcare median |
|---|---|---|
| FY25 | 68.1% | −30.6% |
| FY24 | −18481.4% | −47% |
| FY23 | 2444.4% | −58% |
| FY22 | −1854.4% | −80.4% |
| FY21 | −2925.1% | −71.8% |
| FY20 | −30348.8% | −62.2% |
| FY19 | −1284.3% | −46.2% |
| FY18 | −1051.4% | −49.6% |
| FY17 | −1957.7% | −45.9% |
| FY16 | −7609.3% | −36% |
| FY15 | - | −37.8% |
| FY14 | - | −35.5% |